Home＞ACADEMIA
DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis(May.26.2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin significantly inhibited deterioration in cardiac diastolic function in diabetes patients, according to results of a clinical research sub-analysis announced by Saga University on May 24 ...
(LOG IN FOR FULL STORY)
-
- Expert Cautions against Hasty Discussions on Cost Effective Assessments Apr.20
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President Apr.19
-
Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
Apr.19
-
Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof.
Apr.02
-
Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients
Mar.06
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
